Business Combinations - Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	1 Months Ended
	Aug. 31, 2021	May 31, 2021	Apr. 30, 2017	Dec. 31, 2021
Recognized amounts of identifiable assets acquired and liabilities assumed
Goodwill				$ 50,897
FF Gene Biotech
Considerations
Cash		$ 18,974
Fair value of the Company’s 30% equity interest held before the business combination		3,734
Total Consideration and fair value of equity interest held before business combination		22,708
Considerations			$ 19,000
Recognized amounts of identifiable assets acquired and liabilities assumed
Financial assets		3,181
Reagents and supplies		1,288
Fixed assets		3,874
Other tangible assets		944
Identifiable intangible assets		6,958
Other current liabilities		(2,585)
Notes payable		(5,893)
Recognized amounts of identifiable assets acquired and liabilities assumed, net		7,767
Noncontrolling interest		(8,141)	(8,100)
Goodwill		23,082	$ 23,100	23,100
Total		$ 22,708
Cytometry Specialists, Inc
Considerations
Cash	$ 43,359
Contingent consideration	10,000
Considerations	53,359
Recognized amounts of identifiable assets acquired and liabilities assumed
Debt-free net working capital	4,270
Fixed assets	6,855
ROU assets - operating	4,988
ROU assets - finance	49
Other assets	160
Identifiable intangible assets	30,540
Deferred tax liability	(9,881)
Operating lease liabilities	(4,988)
Finance lease liabilities	(49)
Other liabilities	(6,069)
Recognized amounts of identifiable assets acquired and liabilities assumed, net	25,875
Goodwill	27,484			$ 27,500
Total	$ 53,359